FDA Approves New 10 mg Dosing for XARELTO® (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE) | Johnson & Johnson

FDA Approves New 10 mg Dosing for XARELTO® (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)

10/30/2017

DownloadPDF 98 KB

Multimedia Files:

Questions? Please contact us:

investor-relations@its.jnj.com